INTERPHEX 2021 Rescheduled Due to COVID-19
The event will be rescheduled for Oct. 19–21, 2021 at the Javits Center in New York City.
Reed Exhibitions announced on Nov. 18, 2020 that it is rescheduling its pharmaceutical industry event INTERPHEX—previously postponed to April 20–22, 2021 at the Javits Center in New York City—to Oct. 19–21, 2021 at the same venue due to the continuing spread of COVID-19.
“After extensive consultation and ongoing monitoring of the COVID-19 pandemic, we have made this decision with the wellbeing of all our customers and partners as our highest priority,” said Marie Browne, group vice president, Reed Exhibitions, in a company press release. “We recognize and appreciate how important INTERPHEX is to the industry and to businesses. We are developing additional channels and digital tools to complement the live event in order to serve the industry, support our loyal exhibitors, and to ensure our attendees have access to find the solutions they need to cost effectively develop and manufacture quality products.”
Source: Reed Exhibitions
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
